Navigation Links
Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
Date:7/11/2012

INDIANAPOLIS, July 11, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today negative clinical trial results from study H8Y-MC-HBBM (HBBM) investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering an acute exacerbation of schizophrenia. In study HBBM, pomaglumetad methionil did not separate from placebo in the primary efficacy endpoint in either the overall or predefined genetic subpopulation (based on the Positive and Negative Syndrome Scale, PANSS) at the two doses investigated (40 mg and 80 mg BID). The active control, risperidone, did separate from placebo in both populations. Pomaglumetad methionil was generally well tolerated in this study, with no new safety findings compared to previous trials. Data will be shared at a later date at an appropriate scientific venue.

HBBM was intended to be the first of two clinical trials to support registration of the compound for monotherapy in acute schizophrenia. The second registration clinical trial, H8Y-MC-HBBN (HBBN), is ongoing. The company will conduct an interim analysis of study HBBN which will provide results later in the year. Additionally, Lilly awaits results from the recently concluded study H8Y-MC-HBCO (HBCO). HBCO is a Phase II study exploring pomaglumetad methionil as an adjunctive treatment with atypical antipsychotics. Data from these two studies will help inform decisions on the future development of pomaglumetad methionil. Ongoing clinical trials with pomaglumetad methionil continue.

"Unfortunately negative studies are common in the field of psychiatry and a reality of biopharmaceutical innovation," said Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories. "Despite all of the advances, the need for new and better treatments for those suffering with mental illnesses is among the mo
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Diabetes Announces Once Upon A Time Contest Winner
2. Lilly Statement on Affordable Care Act Ruling by Supreme Court
3. Lilly Statement on PDUFA Vote by Senate
4. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
5. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
6. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
7. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
9. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
10. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
11. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... BCC Research report discusses the medical device technologies in terms ... and opportunities for different devices and regions. It includes forecasts ... the report focuses on technological trends in recent years in ... and Japan . Use ... device technologies market. - Analyze market structure, including segments and ...
(Date:9/18/2014)...  Iliad Neurosciences, Inc., a company focused on the ... Spectrum Disorders (ASD) announced today that it has entered ... for The State University of New York. ... to identify an abnormality in folate transport to the ... expected to be available for research use by physicians ...
(Date:9/18/2014)... , September 18, 2014 ... has updated the incredibly successful Serialisation Countdown calendar to ... PDF, available at pharmaserialisation.com shows the serialisation ... they will be coming into force. For ... a matter of "if", but "when" they will have ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... Annual Superbugs and Superdrugs Conference on ... ... Enanta Pharmaceuticals, a,leader in the development of small molecule ... to,evaluate a new macrolide-related drug class, Bicyclolides, in the treatment,of ...
... to collaborate on latest research technologies, ALBUQUERQUE, ... Inc. (OTC Bulletin Board: BMOD),( http://www.biomoda.com ), a ... entitled "New Non-Invasive Technology for the Early,Detection of ... Annual,Multidisciplinary Meeting of the American Association for the ...
Cached Medicine Technology:Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 2Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 3Biomoda to Present Paper on Enhanced Technology for Early Detection of Lung Cancer at Annual SWARM Meeting 2
(Date:9/18/2014)... 2014 TayganPoint Consulting Group, a ... President and co-founder John Cassimatis was named as ... for 2014, recognizing the region’s top healthcare and ... executive of the year. , The Innovation Awards ... that continue to shape the medical industry in ...
(Date:9/18/2014)... microbes -- don,t worry, it,s a good thing! As ... microbes are bad. Many active enzymes and bacteria are ... as an important part of our digestive system or ... albicans , an opportunistic yeast pathogen and model organism ... healthy personal ecosystem. However, when our immune system is ...
(Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
(Date:9/18/2014)... York, New York (PRWEB) September 18, 2014 ... ) continue to mount in U.S. courts, Bernstein ... has recommended that the U.S. Food & Drug ... new restrictions that, if implemented, could greatly reduce ... Bone, Reproductive and Urologic Drug Advisory Committee, and ...
(Date:9/18/2014)... News) -- Teens and young adults who,ve been mentored ... provides them with greater responsibility and independence early on ... "We found that having a mentor provides a clear ... author, Steve McDonald, an associate professor of sociology at ... release. In conducting the study, published online ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 3Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 4Health News: Mentors May Steer Young People Toward More Rewarding Careers 2
... approach to treatment that focuses on recovery from mental ... acclaim for the Medical College of Georgia Department of ... Project GREAT, or the Georgia Recovery-Based Educational Approach ... to be part of their own care, while also ...
... FRIDAY, Feb. 24 (HealthDay News) -- Sudden Infant Death Syndrome ... German researchers reports. DNA analysis from a small group ... the male children carried a particular enzyme mutation that may ... the case for female SIDS patients. Study author Dr. ...
... Overweight or obese people with chronic kidney disease may suffer ... new study warns. Cleveland Clinic researchers analyzed the eating ... who took part in the U.S. National Health and Nutrition ... percent said they had tried to lose weight in the ...
... Serena Gordon HealthDay Reporter , FRIDAY, Feb. 24 ... on their own take a companion -- usually a spouse ... office visits, researchers report. And they tend to bring ... health care system with another important member of a patient,s ...
... , This release is available in Spanish ... and the university hospital Virgen de las Nieves in Granada ... toxic than that traditionally used and only targets cancerous tissue. ... efficient cancer postoperative treatment for cases of cancer of the ...
... Cells that die naturally generate a lot of internal debris ... leading to diseases such as lupus., Now Georgia Health Sciences ... a woman,s immune system from attacking a fetus also helps ... such as DNA or joints. , The findings point ...
Cached Medicine News:Health News:Psychiatry program garners national education award 2Health News:Psychiatry program garners national education award 3Health News:Gene Might Be a Culprit in Sudden Infant Death for Boys 2Health News:Gene Might Be a Culprit in Sudden Infant Death for Boys 3Health News:Dieting Can Prove Dangerous for Kidney Disease Patients 2Health News:Many Elderly Now Bring Companion on Doctor's Visit 2Health News:Many Elderly Now Bring Companion on Doctor's Visit 3Health News:A new radiotherapy technique significantly reduces irradiation of healthy tissue 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 3
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Duckbill type sharp. 3 mm wide x 8 mm long curved blade. Octagonal handle....
9 mm slightly curved blade. Hexagonal handle....
Medicine Products: